ABSTRACT
Background Studies on middle-aged or individuals with cognitive or cardiovascular impairments, have established that intensive blood pressure (BP) control reduces cognitive decline risk. However, uncertainty exists on differential effects between antihypertensive medications (AHM) classes on this risk, independent of BP-lowering efficacy, particularly in community-dwelling hypertensive older adults.
Methods A post-hoc analysis of the ASPREE study, a randomized trial of low-dose aspirin in adults aged 70+ years (65+ if US minorities) without baseline dementia, and followed for two years post-trial. Cox proportional-hazards regression models were used to estimate associations between baseline and time-varying AHM exposure and incident dementia (an adjudicated primary trial endpoint), in participants with baseline hypertension. Subgroup analyses included prespecified factors, APO ε4 carrier status and monotherapy AHM use.
Results Most hypertensive participants (9,843/13,916; 70.7%) used AHMs. Overall, ‘any’ AHM use was not associated with lower incident dementia risk, compared with untreated participants (HR 0.84, 95%CI 0.70-1.02, p=0.08), but risk was decreased when angiotensin receptor blockers (ARBs) were included (HR 0.73, 95%CI 0.59-0.92, p=0.007). ARBs and β-blockers decreased dementia risk, whereas angiotensin-converting enzyme inhibitors (ACEIs) and diuretics increased risk. There was no association with RAS modulating or blood-brain-barrier crossing AHMs on dementia risk.
Conclusions Overall, AHM exposure in hypertensive older adults was not associated with decreased dementia risk, however, specific AHM classes were with risk direction determined by class; ARBs and β-blockers were superior to ACEIs and other classes in decreasing risk. Our findings emphasize the importance of considering effects beyond BP-lowering efficacy when choosing AHM in older adults.
Competing Interest Statement
Dr. Shah reports being the site principal investigator or sub-investigator for Alzheimer's disease clinical trials for which his institution (Rush University Medical Center) is compensated [Amylyx Pharmaceuticals, Inc., Athira Pharma, Inc., Edgewater NEXT, Eli Lilly & Co., Inc., Genentech, Inc.]. The remaining authors declare that they have no conflict of interests.
Clinical Trial
ASPREE Clinical Trial Registration: Clinicaltrials.gov number, NCT01038583.
Funding Statement
This work was supported by grants (U01AG029824 and U19AG062682) from the National Institute on Aging and the National Cancer Institute at the National Institutes of Health, by grants (334047 and 1127060) from the National Health and Medical Research Council of Australia, and by Monash University and the Victorian Cancer Agency. The funders did not play a role in the study design, collection, analysis and interpretation of the data, nor in the writing of or decision to submit, this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for the ASPREE trial was received from each participating centre in Australia (primary Human Research Ethics Board (HREC) Monash University, approval CF07/3730-2006000745, and the United States. Additionally, the National Institute on Aging, the principal funder of the trial, along with an independent board assigned to monitor data and safety, reviewed the data collected by the trial biannually.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
NONSTANDARD ABBREVIATIONS AND ACRONYMS
- ACEI
- Angiotensin Converting Enzyme inhibitor
- AHM
- Anti-Hypertension Medication
- APOE ε4
- Apolipoprotein E, variant ε4
- ARBs
- Angiotensin receptor blocker
- ASPREE
- ASPirin in Reducing Events in the Elderly
- ASPREE-HTN
- ASPREE Hypertension population
- ASPREE-XT
- ASPREE eXTension observational study
- AT1/AT2/AT4
- Angiotensin II receptor type 1 / 2 / 4
- ATC code
- Anatomical Therapeutic Chemical code
- BB
- Beta-Blocker
- BBB
- Blood-brain-barrier
- CCB
- Calcium Channel Blocker
- CES-D 10
- Centre for Epidemiologic Studies-Depression, 10 item scale
- DBP
- Diastolic blood pressure
- HTN
- Hypertension
- RAS
- Renin Angiotensin System
- SBP
- SBP = Systolic blood pressure
- TC
- Total cholesterol
- 3MS
- Modified Mini Mental Examination
